Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin
- 12 August 2014
- journal article
- research article
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 74 (12), 2157-2164
- https://doi.org/10.1136/annrheumdis-2014-205577
Abstract
Objective Allopurinol, an antihyperuricaemic agent, is one of the common causes of life-threatening severe cutaneous adverse reactions (SCAR), including drug rash with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS) and toxic epidermal necrosis (TEN). The prognostic factors for allopurinol-related SCAR remain unclear. This study aimed to investigate the relationship of dosing, renal function, plasma levels of oxypurinol and granulysin (a cytotoxic protein of SJS/TEN), the disease severity and mortality in allopurinol-SCAR. Methods We prospectively enrolled 48 patients with allopurinol-SCAR (26 SJS/TEN and 22 DRESS) and 138 allopurinol-tolerant controls from 2007 to 2012. The human leucocyte antigen (HLA)-B*58:01 status, plasma concentrations of oxypurinol and granulysin were determined. Results In this cohort, HLA-B*58:01 was strongly associated with allopurinol-SCAR (pConclusions Impaired renal function and increased plasma levels of oxypurinol and granulysin correlated with the poor prognosis of allopurinol-SCAR. Allopurinol prescription is suggested to be avoided in subjects with renal insufficiency and HLA-B*58:01 carriers. An early intervention to increase the clearance of plasma oxypurinol may improve the prognosis of allopurinol-SCAR.Keywords
This publication has 39 references indexed in Scilit:
- An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of GoutCurrent Opinion in Rheumatology, 2014
- The genetics of hyperuricaemia and goutNature Reviews Rheumatology, 2012
- Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with GoutThe Journal of Rheumatology, 2011
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Epidemiology of hypersensitivity drug reactionsCurrent Opinion in Allergy and Clinical Immunology, 2005
- HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProceedings of the National Academy of Sciences of the United States of America, 2005
- GoutNew England Journal of Medicine, 2003
- Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic goutAnnals Of The Rheumatic Diseases, 1998
- The Management of GoutNew England Journal of Medicine, 1996
- Allopurinol Hypersensitivity Syndrome: A ReviewAnnals of Pharmacotherapy, 1993